Publication
Podcast
Supplements and Featured Publications
Andreeff Sheds Light on the Evaluation of the E-selectin Antagonist Uproleselan in AML
Author(s):
In Partnership With:
Dr Andreeff discusses the evaluation of uproleselan for the treatment of patients with acute myeloid leukemia, the rationale for targeting E-selectin in patients with this disease, how uproleselan could amplify the effects of chemotherapy in the treatment of these patients.
Welcome to OncLive On Air®! I’m your host today, Chris Ryan.
OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, sponsored by GlycoMimetics, we had the pleasure of speaking with Michael Andreeff, MD, PhD, about the evaluation of uproleselan for the treatment of patients with acute myeloid leukemia (AML). Dr Andreeff is a professor of medicine and holds the Paul and Mary Haas Chair in Genetics at The University of Texas MD Anderson Cancer Center in Houston, Texas.
In our exclusive interview, Dr Andreeff discussed the novel, first-in-class E-selectin antagonist uproleselan, the rationale for targeting E-selectin in patients with AML, how uproleselan could amplify the effects of chemotherapy in the treatment of these patients, and other ongoing research evaluating uproleselan in combination with other agents.
___
That’s all we have for today! Thank you for listening to this episode of OncLive On Air®, sponsored by GlycoMimetics. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.
For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.
OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.
If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!
Thanks again for listening to OncLive On Air®.
*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.
